HomeUSABreakout Ventures Adds Five New Venture Partners

Breakout Ventures Adds Five New Venture Partners

From left to right, top then bottom row: Sridhar Iyengar, PhD: Founder and Chief Strategy Officer, Elemental Machines; Coco Krumme, PhD: Founder, Leeward Co; Rebecca Nugent, PhD: VP of HTP Operations, Tessera Therapeutics; Walter Solomon: Board Director; Ilan Zipkin, PhD: Founder and Chief Executive Officer, Supercede Therapeutics (Graphic: Business Wire)

Breakout Ventures, a San Francisco, CA-based bioscience investment firm, added new venture partners.

Venture partners include:

Sridhar Iyengar, PhD, a serial founder, angel investor, and advisor to science-driven startups in the Boston ecosystem. He is the founder and Chief Strategy Officer of Elemental Machines, a company integrating hardware, software, and data science solutions to redefine connectivity in laboratory and manufacturing spaces. Iyengar holds over 100 US and international patents and received his Ph.D. from Cambridge University as a Marshall Scholar.

Coco Krumme, PhD, an applied mathematician and founder of Leeward Co, a boutique computational sciences consultancy. She has led data teams in Silicon Valley, taught in the data science programs at UC Berkeley and University of Michigan, and is author of the popular science book Optimal Illusions. Krumme holds a PhD from MIT and a BS from Yale.

Rebecca Nugent, PhD, an R&D executive focused on commercializing biotechnology research in synthetic biology, genomics, and biopharma. She is the VP of HTP Operations at Tessera Therapeutics, a company pioneering genome engineering technology. Nugent led Synthego’s research department and spent six years at Twist Bioscience developing synthetic biology products. She received her PhD from the University of Southern California.

Walter Solomon, who has spent his career driving growth in both Fortune 500 corporations and Inc 5000 start-ups across a wide range of industries including life sciences, chemicals, and consumer products/retail. As the Vice President and Chief Growth Officer for Ashland Inc., Solomon led the company’s transformation into a $6 billion global specialty materials and retail company. He advises numerous portfolio companies of VC and PE firms, including as a board member for Checkerspot, a Breakout Ventures investment. Solomon holds a BS from the University of Virginia.

Ilan Zipkin, PhD, who has been a life science investor and entrepreneur for over 20 years as a partner with institutional and corporate venture funds. Most recently, he was a partner at Aditum Bio, guiding negotiation of therapeutic product in-licenses and new company formation. Zipkin is currently the founder and CEO of Supercede Therapeutics, a small molecule drug development company. Zipkin holds a PhD in cell biology and biochemistry from UCSF.

These industry leaders will lend their experience to diligence new investments and advise Breakout’s portfolio companies on product development and commercialization strategy.

Founded in 2016 and led by Lindy Fishburne, Managing Partner, Breakout Ventures invests in early-stage companies by leveraging technology, biology, and chemistry to build solutions for human health and sustainability. Portfolio companies include Twelve, Immusoft, Ecovative, Cytovale and ZymoChem.

FinSMEs

26/03/2024